Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOPE-3 cardiovascular prevention trial
2007-001493-91Phase 4Completed
- Sponsor
- Population Health Research Institute
- Start
- Jun 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of rosuvastatin and candesartan cilexetil + hydrochlorothiazide in cardiac morbidity (4 arms), sponsored by Population Health Research Institute. Primary endpoint: Primary composite cardiovascular outcome. Started Jun 2007; status: completed.
02
Drugs
rosuvastatincandesartan cilexetil + hydrochlorothiazide
03
Conditions
cardiac morbidity
Beyond the preview
Go deeper on 2007-001493-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001493-91.